Piloting artificial intelligence in claims management is no longer the barrier, operational integration is. Here’s how claims organizations can move beyond proof of concept to realize the full value of AI.
As more states adopt PTSD presumption laws for first responders and other at-risk workers, payers face new challenges in diagnosis, treatment, and long-term claim management. A thoughtful, collaborative approach is key to achieving better outcomes.
In this fictive scenario, a thriving boutique owner’s dream goes up in flames when a hidden electrical hazard and an overlooked insurance gap combine to deliver a devastating financial loss.
Geoeconomic confrontation, cyberattacks, extreme weather and aging systems are amplifying risks across essential infrastructure networks, according to a Gallagher report.
RIMS recognizes Bray and Specialized Bicycle Components’ Emily Buckley for their leadership in embedding risk management into organizational strategy and decision-making.
AI in claims is no longer about insight alone — it’s about embedding intelligence into everyday workflows to drive faster decisions, stronger outcomes, and more human-centered care.
From supply chain disruptions to cloud outages, systemic shocks are no longer theoretical. Industry leaders explain why predicting and preventing cascading losses requires new tools, deeper collaboration, and a fundamentally different approach to risk.
Drowsiness, distraction and aggressive driving consistently precede incidents, and near-collisions are becoming the leading safety metric for fleet risk management, according to Motive’s 2026 road safety report.
As AI rapidly transforms underwriting, claims, and operations, the Associate in Insurance AI™ provides practical skills to evaluate and apply this technology across the insurance value chain.
Insurance risk leaders face near-term economic pressures while bracing for AI-driven risks, according to Emerging Risk Survey by Casualty Actuarial Society and Society of Actuaries.
Allianz survey finds more than half of risk managers view cascading supply chain disruptions as the most plausible Black Swan event for their companies.
Despite declining transaction volume in 2024, life sciences companies are pursuing bigger acquisitions to secure drug portfolios, integrate AI capabilities, and navigate the looming patent cliff.